Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3292882 | 0.74 | CA2 (0.35) | CA12CA1CA9 | |
| SCHEMBL4160204 | 0.73 | KDM4E (0.45) | SMN1; SMN2CA12CA1CA9MAPT | |
| SCHEMBL5274851 | 0.73 | SMN1; SMN2 (0.48) | SMN1; SMN2CA12CA1CA9MAPT | |
| SCHEMBL9526148 | 0.72 | — | — | |
| SCHEMBL951889 | 0.68 | TSHR (0.46) | SMN1; SMN2MAPTKMT2ARAB9ALMNA | |
| SCHEMBL1455628 | 0.65 | TSHR (0.56) | SMN1; SMN2MAPTKMT2ARAB9ALMNA | |
| SCHEMBL1896874 | 0.65 | SMN1; SMN2 (0.50) | SMN1; SMN2CA12CA1CA9MAPT | |
| SCHEMBL7976882 | 0.64 | HTT (0.55) | SMN1; SMN2MAPTKMT2ARAB9ALMNA | |
| N-Nitrosomorpholine SCHEMBL26048320 | 0.63 | — | — | |
| N-Nitrosomorpholine SCHEMBL1578515 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080187978-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2008-08-07 | — | — | US | claimed |
| US-20080064688-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2008-03-13 | — | — | US | claimed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | claimed |
| EP-1773784-A2 | ANTI-INFLAMMATORY MEDICAMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006014290-A2 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-02-09 | — | — | WO | claimed |
| US-20050288286-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2005-12-29 | — | — | US | claimed |
| US-7737283-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | disclosed |
| US-7531566-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-20090105230-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2009-04-23 | — | — | US | disclosed |
| US-20090075986-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20080187978-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2008-08-07 | — | — | US | disclosed |
| US-20080132506-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2008-06-05 | — | — | US | disclosed |
| US-20080064688-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2008-03-13 | — | — | US | disclosed |
| US-7342037-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-03-11 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| EP-1773784-A2 | ANTI-INFLAMMATORY MEDICAMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-04-18 | — | — | EP | disclosed |
| US-7202257-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-04-10 | — | — | US | disclosed |
| WO-2006014290-A2 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20050288286-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064688-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | SMN1; SMN2 3576/4885CA12 2354/4885CA1 1588/4885 |
| US-20090105230-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | SMN1; SMN2 3576/4885CA12 2354/4885CA1 1588/4885 |
| US-20090075986-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | SMN1; SMN2 3576/4885CA12 2354/4885CA1 1588/4885 |
| US-20050288286-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | SMN1; SMN2 3576/4885CA12 2354/4885CA1 1588/4885 |
| US-20070191336-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | SMN1; SMN2 1101/4885CA12 4553/4885CA1 2613/4885 |
| US-20080132506-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | SMN1; SMN2 3576/4885CA12 2354/4885CA1 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.